NCT06145217View on ClinicalTrials.gov

An Drug-drug Interaction Study to Evaluate the Effects of Omeprazole 40mg on the Pharmacokinetics of SPRYCEL®

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 22, 2023

Primary Completion Date

August 22, 2023

Study Completion Date

August 29, 2023

Conditions

Drug-drug Interaction Study

Interventions

DRUG

SPRYCEL® (dasatinib) 100 mg Film-Coated Tablets in combination with Omeprazole Delayed-Release Capsules USP, 40 mg

To evaluate the drug-drug interaction between SPRYCEL® 100 mg and Omeprazole under fasted conditions in healthy, adult, human subjects.

Trial Locations (1)

500037

QPS Bioserve India Pvt Limited, Hyderabad

All Listed Sponsors

lead

Xspray Pharma AB

INDUSTRY

NCT06145217 - An Drug-drug Interaction Study to Evaluate the Effects of Omeprazole 40mg on the Pharmacokinetics of SPRYCEL® | Biotech Hunter | Biotech Hunter